Rapid-Throughput Skeletal Phenotyping of 100 Knockout Mice Identifies 9 New Genes That Determine Bone Strength

Osteoporosis is a common polygenic disease and global healthcare priority but its genetic basis remains largely unknown. We report a high-throughput multi-parameter phenotype screen to identify functionally significant skeletal phenotypes in mice generated by the Wellcome Trust Sanger Institute Mouse Genetics Project and discover novel genes that may be involved in the pathogenesis of osteoporosis. The integrated use of primary phenotype data with quantitative x-ray microradiography, micro-computed tomography, statistical approaches and biomechanical testing in 100 unselected knockout mouse strains identified nine new genetic determinants of bone mass and strength. These nine new genes include five whose deletion results in low bone mass and four whose deletion results in high bone mass. None of the nine genes have been implicated previously in skeletal disorders and detailed analysis of the biomechanical consequences of their deletion revealed a novel functional classification of bone structure and strength. The organ-specific and disease-focused strategy described in this study can be applied to any biological system or tractable polygenic disease, thus providing a general basis to define gene function in a system-specific manner. Application of the approach to diseases affecting other physiological systems will help to realize the full potential of the International Mouse Phenotyping Consortium.

[1]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[2]  Xiaolu Yang,et al.  SUMO E3 ligase activity of TRIM proteins , 2011, Oncogene.

[3]  M. Ishii,et al.  The role of sphingosine 1-phosphate in migration of osteoclast precursors; an application of intravital two-photon microscopy , 2011, Molecules and cells.

[4]  R. Baron,et al.  Wnt signaling and the regulation of bone mass , 2007, Current osteoporosis reports.

[5]  P. Chambon,et al.  Retinoic acid receptors are required for skeletal growth, matrix homeostasis and growth plate function in postnatal mouse. , 2009, Developmental biology.

[6]  B. Everitt An R and S-Plus® Companion to Multivariate Analysis , 2007 .

[7]  J. Harrow,et al.  A conditional knockout resource for the genome-wide study of mouse gene function , 2011, Nature.

[8]  Richard P Lifton,et al.  High bone density due to a mutation in LDL-receptor-related protein 5. , 2002, The New England journal of medicine.

[9]  T. Rachner,et al.  Osteoporosis: now and the future , 2011, The Lancet.

[10]  F. Baas,et al.  Identification of Novel Candidate Oncogenes in Chromosome Region 17p11.2-p12 in Human Osteosarcoma , 2012, PloS one.

[11]  P. Rousseeuw,et al.  Unmasking Multivariate Outliers and Leverage Points , 1990 .

[12]  A. Ito,et al.  Nerve-mast cell and smooth muscle-mast cell interaction mediated by cell adhesion molecule-1, CADM1. , 2008, Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi.

[13]  D. Rimoin,et al.  Nucleotide-sugar transporter SLC35D1 is critical to chondroitin sulfate synthesis in cartilage and skeletal development in mouse and human , 2007, Nature Medicine.

[14]  Kari Stefansson,et al.  Multiple genetic loci for bone mineral density and fractures. , 2008, The New England journal of medicine.

[15]  E. Lander,et al.  A Family of Chondrodysplasias Caused by Mutations in the Diastrophic Dysplasia Sulfate Transporter Gene and Associated with Impaired Sulfation of Proteoglycans a , 1996, Annals of the New York Academy of Sciences.

[16]  Yurii S. Aulchenko,et al.  Twenty bone mineral density loci identified by large-scale meta-analysis of genome-wide association studies , 2009, Nature Genetics.

[17]  W. Van Hul,et al.  The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes. , 2007, Endocrinology.

[18]  P. Rousseeuw Multivariate estimation with high breakdown point , 1985 .

[19]  R. Recker,et al.  Bone biomechanical properties in LRP5 mutant mice. , 2004, Bone.

[20]  S. Khosla,et al.  Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate , 2008, Proceedings of the National Academy of Sciences.

[21]  Miikka Vikkula,et al.  LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development , 2001, Cell.

[22]  L. Vissers,et al.  De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome , 2011, Nature Genetics.

[23]  S. Mundlos,et al.  Heritable diseases of the skeleton. Part I: Molecular insights into skeletal development‐transcription factors and signaling pathways 1 , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  R. H. Bassett,et al.  Optimal bone strength and mineralization requires the type 2 iodothyronine deiodinase in osteoblasts , 2010, Proceedings of the National Academy of Sciences.

[25]  M. Justice Removing the cloak of invisibility: phenotyping the mouse , 2008, Disease Models & Mechanisms.

[26]  Wolfgang Wurst,et al.  A Mouse for All Reasons , 2007, Cell.

[27]  David A. Case,et al.  Structural basis for DNA bending by the architectural transcription factor LEF-1 , 1995, Nature.

[28]  Jacqueline K. White,et al.  Optimising experimental design for high-throughput phenotyping in mice: a case study , 2010, Mammalian Genome.

[29]  A Hofman,et al.  Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study , 2008, The Lancet.

[30]  E. Vilain,et al.  Dimerization of SOX9 is required for chondrogenesis, but not for sex determination. , 2003, Human molecular genetics.

[31]  J. Hess,et al.  Additional sex combs-like 1 belongs to the enhancer of trithorax and polycomb group and genetically interacts with Cbx2 in mice. , 2010, Developmental biology.

[32]  R. Rizzoli,et al.  Bone strength and its determinants , 2003, Osteoporosis International.

[33]  Narmada Thanki,et al.  CDD: specific functional annotation with the Conserved Domain Database , 2008, Nucleic Acids Res..

[34]  S. Cummings,et al.  Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. , 2000, The Journal of clinical endocrinology and metabolism.

[35]  Daniel L. Koller,et al.  Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture , 2012, Nature Genetics.

[36]  E. Wagner Bone development and inflammatory disease is regulated by AP-1 (Fos/Jun) , 2009, Annals of the rheumatic diseases.

[37]  A. Yamaguchi,et al.  The Sphingosine 1-Phosphate Transporter, SPNS2, Functions as a Transporter of the Phosphorylated Form of the Immunomodulating Agent FTY720* , 2010, The Journal of Biological Chemistry.

[38]  M. Taira,et al.  Mammalian phosphoribosyl-pyrophosphate synthetase. , 1995, Advances in Enzyme Regulation.

[39]  M. Drezner,et al.  Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[40]  P Chambon,et al.  EMPReSS: standardized phenotype screens for functional annotation of the mouse genome , 2005, Nature Genetics.

[41]  W C Hutton,et al.  The mechanical properties of bone in osteoporosis. , 1981, The Journal of bone and joint surgery. British volume.

[42]  Hong-Hee Kim,et al.  Sphingosine 1‐phosphate as a regulator of osteoclast differentiation and osteoclast–osteoblast coupling , 2006, The EMBO journal.

[43]  A. Boskey,et al.  Infrared Analysis of the Mineral and Matrix in Bones of Osteonectin‐Null Mice and Their Wildtype Controls , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[44]  R. Hay,et al.  Functional interactions between ubiquitin E2 enzymes and TRIM proteins. , 2011, The Biochemical journal.

[45]  P. Kostenuik,et al.  Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[46]  O. Johnell,et al.  An estimate of the worldwide prevalence and disability associated with osteoporotic fractures , 2006, Osteoporosis International.

[47]  D. Lilley,et al.  HMG box proteins bind to four‐way DNA junctions in their open conformation , 1998, The EMBO journal.

[48]  F. Luyten,et al.  Wnt signaling and osteoarthritis. , 2009, Bone.

[49]  F. Watt,et al.  Necl2 regulates epidermal adhesion and wound repair , 2009, Development.

[50]  M. Amling,et al.  Osteopenia and decreased bone formation in osteonectin-deficient mice , 2000, The Journal of clinical investigation.

[51]  A. Prentice,et al.  Effects of recombinant leptin therapy in a child with congenital leptin deficiency. , 1999, The New England journal of medicine.

[52]  B. Sundberg,et al.  The Evolutionary History and Tissue Mapping of Amino Acid Transporters Belonging to Solute Carrier Families SLC32, SLC36, and SLC38 , 2008, Journal of Molecular Neuroscience.

[53]  Xi He,et al.  Wnt/beta-catenin signaling: components, mechanisms, and diseases. , 2009, Developmental cell.

[54]  G. Maul,et al.  SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins. , 2002, Genes & development.

[55]  T. Hansen,et al.  Mutations in the hepatocyte nuclear factor-1α gene in maturity-onset diabetes of the young (MODY3) , 1996, Nature.

[56]  C. Basilico,et al.  Coevolution of HMG domains and homeodomains and the generation of transcriptional regulation by Sox/POU complexes , 2001, Journal of cellular physiology.

[57]  Yi Zhang,et al.  Molecular cloning of ESET, a novel histone H3-specific methyltransferase that interacts with ERG transcription factor , 2002, Oncogene.

[58]  H. Fukuhara,et al.  TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer , 2001, Nature Genetics.

[59]  Gideon A. Rodan,et al.  Control of osteoblast function and regulation of bone mass , 2003, Nature.

[60]  H. Shibuya,et al.  Nemo-like kinase (NLK) expression in osteoblastic cells and suppression of osteoblastic differentiation. , 2010, Experimental cell research.

[61]  R. Visigalli,et al.  The role of the neutral amino acid transporter SNAT2 in cell volume regulation , 2006, Acta physiologica.

[62]  H. Kronenberg,et al.  Developmental regulation of the growth plate , 2003, Nature.

[63]  Michael C. Nevitt,et al.  Fracture Risk Reduction With Alendronate in Women With Osteoporosis: The Fracture Intervention Trial , 2001 .

[64]  A. F. Mitchell,et al.  The Mahalanobis distance and elliptic distributions , 1985 .

[65]  D. Wellik Hox patterning of the vertebrate axial skeleton , 2007, Developmental dynamics : an official publication of the American Association of Anatomists.

[66]  Y Wang,et al.  Positional cloning of the gene for multiple endocrine neoplasia-type 1. , 1997, Science.

[67]  D. Goldstein,et al.  Uncovering the roles of rare variants in common disease through whole-genome sequencing , 2010, Nature Reviews Genetics.

[68]  S. Ortolani,et al.  Genetics of osteoporosis , 1994, Calcified Tissue International.

[69]  S. O’Rahilly,et al.  Congenital leptin deficiency is associated with severe early-onset obesity in humans , 1997, Nature.

[70]  F. Ashcroft,et al.  Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. , 2006, The New England journal of medicine.

[71]  D. Galas,et al.  Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. , 2001, American journal of human genetics.

[72]  Zhiling Yu,et al.  Impairment of social and emotional behaviors in Cadm1-knockout mice. , 2010, Biochemical and biophysical research communications.

[73]  S. Um,et al.  ASXL1 Represses Retinoic Acid Receptor-mediated Transcription through Associating with HP1 and LSD1* , 2009, The Journal of Biological Chemistry.

[74]  Toshihisa Komori,et al.  Regulation of osteoblast differentiation by transcription factors , 2006, Journal of cellular biochemistry.

[75]  Steve D. M. Brown,et al.  A hearing and vestibular phenotyping pipeline to identify mouse mutants with hearing impairment , 2010, Nature Protocols.

[76]  F. Watt,et al.  Epidermal Cadm1 Expression Promotes Autoimmune Alopecia via Enhanced T Cell Adhesion and Cytotoxicity , 2012, The Journal of Immunology.

[77]  S. Cummings,et al.  Effects of antiresorptive treatment on nonvertebral fracture outcomes , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[78]  T. Südhof,et al.  SynCAM, a Synaptic Adhesion Molecule That Drives Synapse Assembly , 2002, Science.

[79]  William N. Venables,et al.  Modern Applied Statistics with S , 2010 .

[80]  K. Ozato,et al.  TRIM family proteins and their emerging roles in innate immunity , 2008, Nature Reviews Immunology.

[81]  P. Esposito,et al.  Osteogenesis Imperfecta. , 1928, Proceedings of the Royal Society of Medicine.

[82]  C. Löwik,et al.  A new paradigm in the treatment of osteoporosis: Wnt pathway proteins and their antagonists. , 2007, Current opinion in investigational drugs.

[83]  M. Ishii,et al.  Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis , 2009, Nature.

[84]  H. Clevers,et al.  Ancestry and diversity of the HMG box superfamily. , 1993, Nucleic acids research.

[85]  K. Toshimori,et al.  Oligo-Astheno-Teratozoospermia in Mice Lacking RA175/TSLC1/SynCAM/IGSF4A, a Cell Adhesion Molecule in the Immunoglobulin Superfamily , 2006, Molecular and Cellular Biology.

[86]  F. Liu,et al.  TRIM45, a novel human RBCC/TRIM protein, inhibits transcriptional activities of ElK-1 and AP-1. , 2004, Biochemical and biophysical research communications.